Los Angeles-based Aneuvo designed ExaStim to deliver non-invasive, personalized transcutaneous SCS therapy. It supports functional neurorehabilitation for patients paralysis due to spinal cord injury (SCI). The company built its platform on neuromodulation technology designed to enable flexible, scalable, accessible therapy delivery. 

ExaStim’s approval covers both clinic and home use. It’s indicated to improve hand sensation and strength in individuals aged 18 to 17 years old with chronic, non-progressive neurological deficits resulting from incomplete spinal cord injury, when used in conjunction with functional task practice.